Laxmi Organic Industries Discusses Q2FY26 Performance and Project Ramps-Up in Investor Call
Laxmi Organic discussed Q2FY26 results and project updates in an investor call. Revenue and profit declined, but new Dahej and fluorine projects are ramping up, with significant capex underway for future growth.
The impact is medium because while the current quarter's financial performance shows a decline, the announcement provides substantial updates on key growth projects and capital expenditure plans. These strategic initiatives are crucial for the company's long-term trajectory and future revenue generation, balancing out the immediate financial challenges.
The sentiment is neutral due to a mixed performance in Q2FY26, with declines in revenue, EBITDA, and PAT. However, the company is actively executing strategic growth projects like the Dahej facility, fluorine expansion, and Hitachi partnership, which provide a positive outlook for future quarters.
* Laxmi Organic Industries Limited participated in an Investor & Analyst Meet on October 30, 2025, to discuss its Q2FY26 and H1FY26 performance. A transcript of the conference call was enclosed. * The global chemical industry remains demanding due to regional dynamics and supply-side overcapacities, leading to efforts in cost optimization and restructuring. * Q2FY26 Demand Signals: * Packaging, inks, and adhesives: stable demand. * Agro: moderate demand. * Paints and coatings: weak to moderate demand. * Pharmaceutical: stable demand. * Specialty Business: * Has seen an 18%-20% growth trajectory since 2017, with a current market share of 8-9% in diketene derivatives. * Q2FY26 performance was impacted by: (1) an anticipated phase-out of one agrochemical product (accounting for 10% of the specialty business decline), with an alternative mapped; (2) deferred deliveries to global customers, now expected in H2 FY26; and (3) market price moderation (accounting for 7% of the specialty business decline). * A scheduled turnaround at its specialty ketene, diketene setup (Site 2) is underway, expected to conclude by mid-November 2025. * Fluorination Project: * Ramping up, with anticipated revenues closer to 40%-50% of peak revenues (approximately ₹80 crore) in FY26. * A contract has been signed with Hitachi Energy for the production of EconiQ, an eco-efficient gas for SF6-free high-voltage switchgear. This involves a ₹75 crore capex for a 60 metric tonne capacity, expected to be mechanically complete by Q2 FY27. * Dahej Facility: * Phase 1 has received consent to operate and has commenced supplying customers, backed by a long-term supply agreement with a key customer. Volumes will gradually increase. * Phase 2 is anticipated to achieve mechanical completion by the end of H2 FY26, with a steady ramp-up expected in FY27. * Lote Facility: * The world-scale ethyl acetate plant is expected to be mechanically complete by Q4 FY26. * Q2FY26 Financial Highlights: * Revenue declined by 9% year-on-year. * Specialty revenue declined by 20%, and Essentials revenue declined by 5% (due to price linked to feedstock, volumes were in line). * Gross margin stood at 33.1% (vs 30.8% in Q1FY26 and 35.8% last year). * Total expenses declined by approximately 5% year-on-year due to cost controls. * EBITDA was approximately ₹37 crore (vs ₹74 crore last year), with an EBITDA margin of 5.3% (vs 9.7%). * PAT declined to ₹11 crore (vs ₹28 crore last year). * Cash flow from operations remained robust at ₹153 crore. * Debt-to-equity ratio is 0.17. * The company expects to incur ₹400-₹500 crore in term loans by H2 FY26 for its capex cycle. * A GST incentive of ₹23.4 crore (₹234 million) was recognized as part of operating P&L/sales and revenue from operations. * EBITDA for Essentials was 2%, and for Specialty, it was 8.2%. * Capex Plan (₹1,100 crore): * Approximately ₹800 crore is expected to be capitalized by FY26, with the remainder in FY27. A significant portion of this capex is for the Dahej facility.
What to do with a filing like this
Laxmi Organic Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Laxmi Organic Industries Limited. Read the original for the full detail.